Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data

Clinical Genitourinary Cancer

Volumn 13, Issue 2, 2015, Pages 137-141

  Iacovelli, Roberto ^a   Santoni, Matteo ^b   Verzoni, Elena ^a   Grassi, Paolo ^a   Testa, Isabella ^a   De Braud, Filippo ^a   Cascinu, Stefano ^b   Procopio, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

inhibitors; mRCC; mTOR; Second line; Sequence of therapy

Indexed keywords

EVEROLIMUS; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COMORBIDITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; KIDNEY METASTASIS; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; TIME TO TREATMENT; TREATMENT OUTCOME; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIBLIOGRAPHIC DATABASE; CARCINOMA, RENAL CELL; COMPARATIVE STUDY; KIDNEY NEOPLASMS; MORTALITY; SURVIVAL;

CARCINOMA, RENAL CELL; DATABASES, BIBLIOGRAPHIC; EVEROLIMUS; HUMANS; KIDNEY NEOPLASMS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; SIROLIMUS; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84924363912     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.07.006     Document Type: Article

References (32)

1. American Cancer Society Cancer Facts & Figures 2013 2013 American Cancer Society Atlanta
2. J. Ferlay, E. Steliarova-Foucher, and J. Lortet-Tieulent Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 2013 1374 1403
3. F. Bray, J.S. Ren, and E. Masuyer Global estimates of cancer prevalence for 27 sites in the adult population in 2008 Int J Cancer 132 2013 1133 1145
4. S.P. Gunningham, M.J. Currie, and C. Han Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia Cancer Res 61 2001 3206 3211
5. A. Palazzo, R. Iacovelli, and E. Cortesi Past, present and future of targeted therapy in solid tumors Curr Cancer Drug Targets 10 2010 433 461
6. R.J. Motzer, M. Mazumdar, and J. Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
7. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
8. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon-alpha, or both for advanced renal cell carcinoma N Eng J Med 356 2007 2271 2281
9. M.R. Harrison, D.J. George, and M.S. Walker "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy Clin Genitourin Cancer 11 2013 441 450
10. F. Stenner-Liewen, V. Grünwald, and R. Greil The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma Expert Rev Anticancer Ther 13 2013 1021 1033
11. R.J. Motzer, B. Escudier, and S. Oudard A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind randomized placebo controlled phase III trial Lancet 372 2008 449 456
12. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
13. J.P. Higgins, S.G. Thompson, and J.J. Deeks Measuring inconsistency in metaanalyses BMJ 327 2003 557 560
14. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
15. C.B. Begg, and M. Mazumdar Operating characteristics of a rank correlation test for publication bias Biometrics 50 1994 1088 1101
16. M. Egger, G. Davey Smith, and M. Schneider Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
17. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
18. C.C. Chen, G.P. Hess, and Z. Liu Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma Clin Genitourin Cancer 10 2012 256 261
19. M.K. Wong, H. Yang, and J.E. Signorovitch Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a U.S. medical record review Curr Med Res Opin 30 2014 537 545
20. N. Alimohamed, J.L. Lee, and S. Srinivas A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma Clin Genitourin Cancer 12 2014 e127 e131
21. R. Iacovelli, G. Cartenì, and M. Milella Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib Can Urol Assoc J 8 2014 E121 E125
22. National Comprehensive Cancer Network (NCCN) guidelines. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed March 1, 2014.
23. European Society of Medical Oncology (ESMO). Clinical practice guidelines by tumour type. Available at: http://www.esmo.org/Guidelines-Practice/Clinical-Practice-Guidelines. Accessed March 1, 2014.
24. R. Danesi, J.P. Boni, and A. Ravaud Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications Cancer Treat Rev 39 2013 784 792
25. R.J. Motzer, C.H. Barrios, and T.M. Kim Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC) (abstract 4504) J Clin Oncol 2013 31
26. M.J. Mackenzie, B.I. Rini, and P. Elson Temsirolimus in VEGF-refractory metastatic renal cell carcinoma Ann Oncol 22 2011 145 148
27. M. Milella, G. Di Lorenzo, and A. Felici Medical optimization of Torisel (MOTOR): a phase II trial of temsirolimus as second-line treatment for advanced RCC by the Italian kidney cancer group (GIR) (abstract 846P) Ann Oncol 2012 23
28. T.E. Hutson, B. Escudier, and E. Esteban Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 32 2014 760 767
29. Iacovelli R, Palazzo A, Trenta P, et al. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment. Am J Clin Oncol, Published online Feb 5, 2013. http://dx.doi.org/10.1097/COC.0b013e31827de888.
30. J. Busch, C. Seidel, and B. Erber Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma Eur Urol 64 2013 62 70
31. R. Iacovelli, G. Cartenì, and C.N. Sternberg Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort Eur J Cancer 49 2013 2134 2142
32. A. Levy, J. Menard, and L. Albiges Second line treatment of metastatic renal cell carcinoma: the Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients Eur J Cancer 49 2013 1898 1904